NCT06495281Completed
Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
A Observational Study to Evaluate Effectiveness, Safety of Triple Combination Therapy of Zemidapa and Metformin in Patients With Type 2 DM Who Received Double or Triple Combination Therapy Including DPP4-inhibitor Other Than Gemigliptin
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the effectiveness and safety of the triple combination therapy of Zemidapa Tab. and Metformin in patients with type 2 diabete mellitus
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2044 (actual)
- First submitted
- 2 Jul 2024
- Start date
- 26 Oct 2023
- Primary completion date
- 3 Dec 2025
- Lead sponsor
- LG Chem
- Diseases
- Type 2 diabetes
- NCT number
- NCT06495281
What you commit to
- Study type: Observational
- Participants enrolled: 2044
- From 26 Oct 2023 to the primary completion date, 3 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients contraindicated for the approved use of Zemidapa Tab. or have participated in another clinical study within 12 weeks
Who the study is looking for
- type 2 DM Patients who are receiving one of the following three therapies during which the patients are prescribed with Zemidapa Tab. for the first time at the discretion of the attending physician:
- Double combination therapy (Metformin and a DPP-4 inhibitor other than Gemigliptin)
- Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and a SGLT-2 inhibitor)
- Triple combination therapy (Metformin, a DPP-4 inhibitor other than Gemigliptin, and Sulfonylurea \[SU\])
- patients with HbA1c results and who signed the written consent form
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chonnam National University Hwasun Hospital Coordinator of this site? Confirm its status | Hwasun | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.